Libtayo

Sanofi and Regeneron's I-O med Libtayo, on a roll, puts up basal cell carcinoma win
Sanofi and Regeneron's I-O med Libtayo, on a roll, puts up basal cell carcinoma win
Fierce Pharma
Sanofi
Regeneron
Libtayo
basal cell carcinoma
skin cancer
clinical trials
Flag link:
Regeneron defends bid to challenge Merck in lung cancer
Regeneron defends bid to challenge Merck in lung cancer
Biopharma Dive
Regeneron
Libtayo
Merck
Keytruda
immuno-oncology
lung cancer
Flag link:
Sanofi axes cancer combo, early next-gen diabetes drug
Sanofi axes cancer combo, early next-gen diabetes drug
Fierce Biotech
Sanofi
R&D
diabetes
cancer
isatuximab
Libtayo
Flag link:
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
Flag link:
Inovio Closes Enrollment in Brain Cancer Study Before Time
Inovio Closes Enrollment in Brain Cancer Study Before Time
Yahoo/Zacks.com
Inovio
clinical trials
INO-5401
INO-9012
Libtayo
glioblastoma
Flag link:
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
Flag link:
Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron
Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron
Biopharma Dive
Regeneron
Libtayo
earnings
CSCC
drug launches
Flag link:
Regeneron, Sanofi Win Approval for Their First Immuno-Oncology Drug
Regeneron, Sanofi Win Approval for Their First Immuno-Oncology Drug
Bloomberg
Regeneron
Sanofi
Libtayo
immuno-oncology
skin cancer
FDA
Flag link:

Pages